At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
SCH-1 +1 moredrug
Likely dose
Not stated in record
Key inclusion· 4
- ✓Acute conjunctivitis presenting within 72 hours of initial ocular symptoms
- ✓Age ≥18 years
- ✓Both cardinal signs of acute conjunctivitis: bulbar conjunctival injection rated ≥mild (1) and conjunctival discharge/exudates rated ≥mild (1)
- ✓Capable of understanding study purpose and risks, and able to give informed consent
Key exclusion· 7
- ✕Conjunctivitis symptom onset >72 hours prior to enrollment
- ✕Corneal ulcer, endophthalmitis, or other confounding ocular infection
- ✕Chronic topical anti-inflammatory medication use
- ✕Known steroid glaucoma responder status
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Masked, Placebo-Controlled, Randomized, Phase II Clinical Trial To Assess The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis
In Brief
A Phase 2 clinical trial evaluating SCH-1 and Placebo for Acute Infectious Conjunctivitis (Disorder). Completed, enrolled 30 participants across 1 site.
Detailed Summary
The objective of this study is to evaluate the efficacy of Sasch1, a novel anti-infective eyedrop, in the treatment of acute infectious conjunctivitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartMar 2021
Primary CompletionMar 2022
First PostedMay 2022
TodayJul 2026
First PostedMay 2, 2022
Enrollment StartMar 1, 2021
Primary CompletionMar 28, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.2 years ago
Interventions
SCH-1drug
Novel anti-infective eyedrop
Placebodrug
SCH-1 vehicle minus active components eyedrop